The study investigated the sustain drug release ability of Sus scrofa domesticus (SSD) fat in comparison with carnauba wax in
ibuprofen matrix granule formulations. SSD fat was extracted by wet rendering and used to prepare ibuprofen granules at varying
concentrations of the fat and carnauba wax (2.5-10%w/w) and maize starch mucilage (15%w/w). Granules were evaluated for
micromeritic parameters and drug-excipient interaction using Differential scanning calorimetry (DSC) and Fourier transform infrared
(FTIR) spectroscopy. The granules were packed in hard gelatin capsules and their in vitro drug release and release kinetics evaluated.
SSD fat granules exhibited poor flow properties with angles of repose ≤ 40.40° and Carr’s indices≤38%while those of carnauba wax
were free flowing with angles of repose ≤ 31°Cand Carr’s indices ≤ 19%. DSC and FTIR analyses showed no interaction between the
fat and ibuprofen. Drug release from the granules decreased with increase in fat and wax concentrations. Granules formulated with
5.0-10%w/w of the SSD fat exhibited superior drug retardation within 4 h with percentage release of 43, 37 and 27%, respectively, as
against the 50% release of granules with 10%w/w of carnauba wax. Drug release from the SSD fat granules fitted with the
Korsmeyer-Peppas model, indicating a Super Case-II diffusion mediated drug release mechanism. The drug release profiles of
ibuprofen granules formulated with SSD fat showed significant drug release retardation and were superior to those prepared with
carnauba wax at test concentrations. Hence the SSD fat will find potential application as a matrix former in sustained or controlled
release preparations.
Keywords: Sus scrofa domesticus, ibuprofen, granules, sustained release